Table 1. The correlation between clinical characteristic parameters and the expression of NTRK2 in LUAD.
| Variables | Number | Mean ± SD | P |
|---|---|---|---|
| Gender | 0.007 | ||
| Male | 179 | 5.25 ± 1.90 | |
| Female | 212 | 5.78 ± 1.95 | |
| Radiation therapy | 0.640 | ||
| Yes | 6 | 5.12 ± 1.31 | |
| No | 89 | 5.48 ± 1.82 | |
| Kras mutation found | 0.454 | ||
| Yes | 14 | 5.48 ± 1.89 | |
| No | 34 | 5.88 ± 1.54 | |
| Pathologic T | 0.021 | ||
| T1/T1a/T1b | 122 | 6.01 ± 1.94 | |
| T2/T2a/T2b | 218 | 5.35 ± 2.01 | |
| T3 | 34 | 5.29 ± 1.43 | |
| T4 | 15 | 5.09 ± 1.52 | |
| TX | 2 | 4.36 ± 1.56 | |
| Pathologic N | 0.875 | ||
| N0 | 252 | 5.52 ± 1.86 | |
| N1 | 71 | 5.59 ± 1.89 | |
| N2 | 61 | 5.55 ± 2.32 | |
| NX | 5 | 4.85 ± 2.40 | |
| Pathologic M | 0.006 | ||
| M0 | 255 | 5.38 ± 1.85 | |
| M1/M1a/M1b | 16 | 4.86 ± 2.20 | |
| MX | 117 | 5.99 ± 2.04 | |
| Pathologic stage | 0.471 | ||
| Stage I/IA/IB | 211 | 5.63 ± 1.89 | |
| Stage IIA/IIB | 94 | 5.45 ± 1.78 | |
| Stage IIIA/IIIB | 68 | 5.52 ± 2.25 | |
| Stage IV | 17 | 4.89 ± 2.14 | |
| Race | 0.758 | ||
| White | 314 | 5.60 ± 1.92 | |
| Black or African American | 23 | 5.41 ± 2.26 | |
| Asian | 5 | 5.07 ± 1.12 | |
| Tobacco smoking history | 0.097 | ||
| Current reformed smoker for > 15 years | 94 | 5.84 ± 2.06 | |
| Current reformed smoker for < or = 15 years | 131 | 5.38 ± 1.95 | |
| Current reformed smoker, duration not specified | 2 | 5.15 ± 1.34 | |
| Lifelong non-smoker | 61 | 5.91 ± 1.75 | |
| Current smoker | 91 | 5.21 ± 1.97 | |
| Age at initial pathologic diagnosis | 0.036 | ||
| ≤60 | 125 | 5.25 ± 1.86 | |
| >60 | 248 | 5.69 ± 1.94 | |
| EGFR mutation result | 0.303 | ||
| Exon 19 deletion | 7 | 5.07 ± 1.26 | |
| L858R | 3 | 6.47 ± 1.00 | |
| Other | 9 | 5.94 ± 1.58 |